

1 **Intrinsic and effective severity of COVID-19 cases infected with the ancestral**
2 **strain and Omicron BA.2 variant in Hong Kong**

3

4 Jessica Y. Wong¹, Justin K. Cheung¹, Yun Lin¹, Helen S. Bond¹, Eric H. Y. Lau^{1,2},
5 Dennis K. M. Ip¹, Benjamin J. Cowling^{1,2}, Peng Wu^{1,2}

6

7 **Affiliations:**

8 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control,
9 School of Public Health, Li Ka Shing Faculty of Medicine, The University of
10 Hong Kong, Hong Kong Special Administrative Region, China

11 2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and
12 Technology Park, New Territories, Hong Kong Special Administrative
13 Region, China

14

15 **Corresponding author:**

16 Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The
17 University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong

18 Tel: +852 3917 6711; Email: bcowling@hku.hk

19

20 Word count (abstract): 280

21 Word count (main text): 3,142

22

23 Keywords: COVID-19, intrinsic, severity, SARS-CoV-2, Omicron

24

25 **ABSTRACT**

26 **Background:** Understanding severity of infections with SARS-CoV-2 and its variants
27 is crucial to inform public health measures. Here we used COVID-19 patient data
28 from Hong Kong to characterise the severity profile of COVID-19 and to examine
29 factors associated with fatality of infection.

30 **Methods:** Time-varying and age-specific effective severity measured by case-
31 hospitalization risk and hospitalization risk was estimated with all individual COVID-
32 19 case data collected in Hong Kong from 23 January 2020 through to 26 October
33 2022 over six epidemic waves, in comparison with estimates of influenza
34 A(H1N1)pdm09 during the 2009 pandemic. The intrinsic severity of Omicron BA.2
35 was compared with the estimate for the ancestral strain with the data from
36 unvaccinated patients without previous infections. Factors potentially associated with
37 the fatality risk of hospitalized Omicron patients were also examined.

38 **Results:** With 32,222 COVID-19 hospitalizations and 9,669 deaths confirmed over 6
39 epidemic waves in Hong Kong, the time-varying hospitalization fatality risk
40 dramatically increased from below 10% before the largest fifth wave of Omicron
41 BA.2, to 41% during the peak of the fifth wave when hospital resources were severely
42 constrained. The age-specific fatality risk in unvaccinated hospitalized Omicron cases
43 was comparable to the estimates for unvaccinated cases with the ancestral strain.
44 During epidemics predominated by Omicron BA.2, the highest fatality risk was
45 amongst unvaccinated patients aged ≥ 80 years and the risk was inversely associated
46 with the number of vaccination doses received.

47 **Conclusions:** Omicron has comparable intrinsic severity to the ancestral Wuhan
48 strain although the effective severity is substantially lower in Omicron cases due to
49 vaccination. With a moderate-to-high coverage of vaccination, hospitalized COVID-

50 19 patients caused by Omicron subvariants appeared to have similar age-specific risks

51 of fatality to patients hospitalized with influenza A(H1N1)pdm09.

52

53 INTRODUCTION

54 Hong Kong successfully suppressed four epidemic waves of infection with the
55 ancestral strain of SARS-CoV-2 during the first two years of the pandemic, with
56 12,631 RT-PCR confirmed infections (1.7 cases per 1,000 population) and 213 deaths
57 reported by the end of 2021 [1]. Serologic data confirmed that below 1% of the
58 population had been infected over the same period [2]. However, a large community
59 epidemic caused by Omicron subvariant peaked in early March 2022 [3, 4], leading to
60 over 1.1 million confirmed cases (164.3 cases per 1,000 population) and 9,157 deaths.
61 Two COVID-19 vaccines, the inactivated (CoronaVac, Sinovac) and the mRNA
62 vaccine (BNT162b2, BioNTech/Fosun Pharma), were made available in Hong Kong
63 in early 2021. As of 1 January 2022, approximately 70% of the Hong Kong
64 population aged 3 years or above had received at least two doses of vaccination [5]
65 although vaccination uptake was lower in older adults [6].

66

67 The severity profile of SARS-CoV-2 infections is one of the major determinants for
68 assessing potential health impact of epidemics on a population [7]. One measure of
69 infection severity is the “hospitalization fatality risk” (HFR). This describes the risk
70 of death among hospitalized cases with laboratory-confirmed SARS-CoV-2 infections
71 [8], which comprise a smaller and more homogenous subgroup of infected individuals
72 requiring admission for healthcare than all laboratory-confirmed cases. A related
73 measure of severity is the risk of hospitalization among all cases, i.e. the case
74 hospitalization risk (CHR). The CHR multiplied by the HFR should approximate the
75 fatality risk among all confirmed cases, i.e. the case fatality risk (CFR).

76

77 Here, we analyzed detailed individual case data from Hong Kong, to quantify the
78 overall and temporal patterns of COVID-19 severity in Hong Kong, and identify
79 factors associated with mortality among hospitalized COVID-19 cases. Because
80 Omicron BA.2 was the first strain of COVID-19 to circulate widely in Hong Kong we
81 also aim to estimate the intrinsic severity of SARS-CoV-2 variants using data on
82 infections in unvaccinated individuals.

83

84 **METHODS**

85 *Sources of data*

86 Individual data on all laboratory-confirmed COVID-19 cases infected locally in Hong
87 Kong from 23 January 2020 to 26 October 2022 were obtained from the Hospital
88 Authority and Centre for Health Protection [5]. RT-PCR was used exclusively for
89 confirmation of COVID-19 until 25 February 2022 when a positive rapid antigen test
90 was also accepted as laboratory confirmation [9]. From 7 June 2022 onwards,
91 individuals reporting a positive rapid antigen test were issued with a compulsory
92 testing notice and required to undergo PCR testing within the next two days, and any
93 individuals with negative PCR tests were not counted as COVID-19 cases [10].
94 Demographic, clinical and epidemiological information was collected for individual
95 patients, including age, sex, comorbidities, oxygen saturation levels measured by the
96 pulse oximetry in hospital, severity outcome at discharge, vaccination status, use of
97 nirmatrelvir-ritonavir (Paxlovid) or molnupiravir, residence in care homes for the
98 elderly (RCHE), dates of COVID-19 vaccination for individual doses, laboratory
99 confirmation, hospital admission, death and discharge. Our study received ethical
100 approval from the Institutional Review Board of the University of Hong Kong.

101

102 Up to 14 February 2022, all laboratory-confirmed COVID-19 cases in Hong Kong
103 were admitted into hospital for isolation, and from 15 February onwards, given the
104 rapidly increasing number of COVID-19 cases and limited hospital capacity, only
105 those requiring hospital medical care were admitted. In this study, we defined
106 hospitalized cases as COVID-19 patients confirmed by RT-PCR or rapid antigen test
107 and clinically classified as a severe, critically ill or fatal case based on assessment of
108 oxygen desaturation, use of medication and procedure, and information such as A&E
109 departmental visits and ICU admissions from clinical records, i.e., cases requiring
110 healthcare in hospital. Detailed information on severity classification of COVID-19
111 cases is shown in Appendix. We used data on patients with laboratory confirmation of
112 SARS-CoV-2 infection obtained in the 14 days preceding hospital admission in the
113 analysis on HFR, and used data on all patients tested positive for SARS-CoV-2 either
114 by RT-PCR or rapid antigen test in the analysis of CHR.

115

116 For comparison, we used the data obtained from the Hospital Authority on all
117 individual patients with laboratory-confirmed A(H1N1)pdm09 infection identified
118 during May-December 2009 when influenza A(H1N1)pdm09 virus was first
119 circulating and monovalent H1N1pdm09 vaccines had not been widely used in Hong
120 Kong [11], including age, sex, dates of admission into hospital and intensive care unit,
121 dates of receipt of oseltamivir treatment and death.

122

123 *Statistical analysis*

124 All COVID-19 cases confirmed in each epidemic wave or period of wave were
125 examined in terms of age, sex, severity status and delay distributions. We estimated
126 the effective severity of COVID-19 with the case hospitalization risk (CHR) and the

127 hospitalization fatality risk (HFR). The weekly CHR was estimated as the reported
128 weekly number of hospitalized COVID-19 cases divided by the weekly total number
129 of confirmed cases allowing for a mean lag of 3 days from case notification to
130 hospitalization. The weekly HFR was calculated as the proportion of fatal cases
131 (eventual number of deaths occurred by the end of the study period) among all
132 hospitalized cases admitted in a particular week. We estimated the CHR and HFR in
133 time periods during which at least 35 confirmed cases and at least 15 confirmed
134 hospitalized cases were reported per week in 4 or more consecutive weeks in order to
135 provide effective comparisons between different epidemic waves avoiding large
136 uncertainties from very small case numbers. We also estimated the age-stratified CHR
137 and HFR with the same data for five age groups: <18 years, 18-44 years, 45-64 years,
138 65-79 years and ≥ 80 years for each pre-defined epidemic wave over the study period.
139
140 The data on COVID-19 cases without vaccination in Hong Kong before widespread
141 of Omicron in wave 5 particularly in older adults with a low vaccination coverage
142 allowed us to assess the intrinsic severity of SARS-CoV-2. We determined the HFR
143 among hospitalized cases at age of <65, 65-79 and ≥ 80 years with complete
144 comorbidity information. We also estimated the age-specific relative risk in
145 logarithmic scale as the HFR in the early part of the fifth wave divided by the HFR in
146 waves 1-4. Cases included in the analysis were confirmed before 14 February 2022
147 without receiving any dose of COVID-19 vaccination more than 14 days prior to
148 confirmation of COVID-19 and without a recorded previous infection. We applied
149 logistic regression models to the daily unvaccinated hospitalized COVID-19 cases
150 confirmed in the early part of the fifth wave and earlier epidemic waves to examine
151 factors potentially associated with the intrinsic fatality risk of SARS-CoV-2. In the

152 regression model, we adjusted for age group, gender, comorbidities, and RCHE status.
153 Age-specific HFR estimates were also obtained for unvaccinated cases confirmed in
154 wave 6 for comparison.

155

156 Omicron BA.2 caused the largest epidemic wave 5 in Hong Kong since January 2022
157 extending to wave 6 in May-August 2022. We estimated the HFR with cases
158 confirmed during the period predominated by Omicron BA.2 by vaccine dose and
159 type to illustrate the potential protection provided by COVID-19 vaccination. We
160 determined the vaccine-related relative risk in logarithmic scale for the three age
161 groups as the HFR among cases with a specific vaccine dose combination divided by
162 the HFR among cases that did not receive any dose of COVID-19 vaccination. We
163 performed a similar regression analysis to compare the risk of mortality for patients
164 confirmed in wave 5. In the model, we further adjusted for vaccination type and dose,
165 antiviral use and period of case confirmation.

166

167 We estimated the HFR of influenza A(H1N1)pdm09 with cases confirmed in 2009 as
168 the division of cumulative number of deaths by the cumulative number of laboratory-
169 confirmed hospitalized cases who were treated with oseltamivir or admitted into an
170 intensive care unit during hospital stay. All analyses were conducted with R version
171 4.1.0 (R Foundation for Statistical Computing, Austria).

172

173 **RESULTS**

174 The periods of spread of SARS-CoV-2 in Hong Kong can be divided into six
175 epidemic waves, including four prior to the widespread uptake of vaccines, a large
176 fifth wave predominated by Omicron BA.2 between January and May 2022, and a

177 sixth wave driven by Omicron BA.2 and BA.4/5 subvariants (Figure 1). A total of
178 1,979, 22,805 and 7,438 COVID-19 cases were hospitalized for treatment in waves 1-
179 4, wave 5 and wave 6, respectively. Of all the deaths, 88.8% (8,586/9,669) occurred
180 within 28 days of confirmation, and 98.7% (9,548/9,669) occurred within 90 days. In
181 the peak period of wave 5 (wave 5b, between 14 February and 29 April 2022), 0.8%
182 (4/491), 9.6% (62/646), 22.7% (568/2,504), 31.5% (1,887/5,986) and 46.0%
183 (5,832/12,667) of the hospitalized cases were fatal in age groups <18, 18-44, 45-64,
184 65-79 and ≥ 80 years, respectively (Appendix). The median admission-to-death
185 intervals decreased from 18 days in waves 1-4 to 8 days in the peak period of wave 5.
186 The median admission-to-discharge intervals were very similar, decreasing from 17
187 days to 11 days in waves 1-4 to peak period of wave 5 respectively.

188

189 From January 2020 to October 2022, the smoothed estimate of weekly CHR gradually
190 decreased from 15.9% at the end of wave 3 to 10.5% at the end of wave 4 (Figure 1).
191 In comparison, the weekly HFR estimates similarly declined from 18.1% (95% CI:
192 9.2%, 27.1%) to 8.3% (95% CI: 3.0%, 13.5%) during the same time period. In waves
193 5-6, CHR estimates were relatively stable at low levels (around 0.7%) while the HFR
194 estimates increased substantially from 3.4% (95% CI: 0.0%, 7.7%) in late January
195 2022, peaked at 41.3% (95% CI: 37.9%, 44.8%) in early March before declining to
196 12.2% (95% CI: 7.9%, 16.4%) by the end of October.

197

198 The highest hospitalization risk was observed in cases aged ≥ 65 years (8.2%, 95% CI:
199 8.1%, 8.3%) in wave 5, similar to cases at the same age (5.2%, 95% CI: 5.0%, 5.3%)
200 in wave 6 (Figure 2). The CHR of cases aged 45-64 and ≥ 65 years in waves 1-4
201 appeared to be approximately six times the risk in those at the same age in wave 5

202 (50.0%, 95% CI: 47.8%, 52.4%). The fatality risk of hospitalized cases aged ≥ 65
203 years (41.1%, 95% CI: 40.4%, 41.8%) in wave 5 doubled the risk in individuals in the
204 same age group in waves 1-4 (19.7%, 95% CI: 17.2%, 22.4%) and wave 6 (17.0%,
205 95% CI: 16.0%, 18.0%), and the pattern remained the same for 45-64 years. The HFR
206 estimates were comparable between hospitalized influenza A(H1N1)pdm09 cases in
207 2009 and COVID-19 cases confirmed during wave 6 (Figure 2B).

208

209 There were 22,604 COVID-19 patients hospitalized in wave 5 between 31 December
210 2021 and 22 May 2022 (Table 1). After accounting for factors associated with
211 mortality, individuals with at least one dose of BNT162b2 or CoronaVac had
212 significantly lower odds of mortality than those unvaccinated, with the lowest odds
213 observed in individuals with three doses of BNT162b2 (OR: 0.31, 95% CI: 0.18,
214 0.49). In addition to at an older age (65-79 years and ≥ 80 years vs 45-64 years), being
215 an RCHE resident, having malignant neoplasms or cardiovascular diseases, and
216 confirmed during the peak period were associated with an increased odds of mortality.
217 Female cases, at a younger age or being treated with antivirals (Paxlovid and
218 molnupiravir) had a lower odds of being fatal.

219

220 There were 1,974 and 186 unvaccinated COVID-19 patients hospitalized in waves 1-4
221 and wave 5a, respectively, included in our analysis of intrinsic severity (Table 2). The
222 age-specific estimates of HFR for cases ≥ 80 years (39.7%, 95% CI: 28.5%, 51.9%)
223 and 65-79 years (19.3%, 95% CI: 10.0%, 31.9%) confirmed in wave 5a were similar
224 to the corresponding estimates of 39.0% (95% CI: 33.1%, 45.0%) and 11.4% (95%
225 CI: 9.0%, 14.1%) for cases in waves 1-4 (Figure 3). No significant differences in
226 fatality risk were observed for hospitalized cases in wave 5a relative to those in waves

227 1-4 across all age groups. After accounting for factors potentially associated with
228 mortality, hospitalized cases confirmed in wave 5a showed a similar fatality risk to
229 the cases from waves 1-4 (OR: 1.08, 95% CI: 0.61, 1.83). The odds of mortality were
230 significantly higher in individuals aged 65-79 years (OR: 4.80, 95% CI: 2.94, 8.26)
231 and ≥ 80 years (OR: 20.81, 95% CI: 12.66, 35.95) than in individuals aged 45-64
232 years.

233

234 Among cases hospitalized in non-peak periods of wave 5 and the first half of wave 6
235 (wave 5a from 31 December 2021 to 13 February 2022, and waves 5c and 6a from 30
236 April to 30 August 2022) with Omicron BA.2 predominant, mean estimates of the
237 fatality risk were largely higher in unvaccinated patients and those receiving fewer
238 doses of vaccine in age groups < 65 , 65-79 and ≥ 80 years except for those with two
239 doses of BNT162b2 showing a higher mean estimate of HFR than cases receiving one
240 dose only or 2-dose CoronaVac among cases aged < 65 years (Appendix). Relative
241 risk estimates showed that vaccination had a considerable effect in reducing fatality
242 risk, especially for those who received at least two doses of CoronaVac or BNT162b2
243 in ≥ 80 years.

244

245 **DISCUSSION**

246 Infections with the Omicron variant were originally recognized as being milder than
247 with other variants [12] although it has been challenging to determine whether the
248 attenuated severity of Omicron infections is due to an increased competency in
249 infecting and replicating in the upper respiratory tract [13], or acquired immunity
250 from previous infection and/or vaccination in affected populations [14]. Our analysis
251 of intrinsic severity was conducted based on fatalities in unvaccinated COVID-19

252 patients admitted into hospital for treatment in Hong Kong during epidemic waves
253 predominated by the ancestral Wuhan strain or Omicron BA.2 during January 2020 –
254 February 2022 with a relatively low population coverage of COVID-19 vaccines
255 especially in the elderly. The estimates of HFR indicated that Omicron BA.2 had a
256 similar intrinsic severity to infections with the ancestral strain (Table 2).
257 Comparatively lower fatality risk in hospitalized COVID-19 patients infected with the
258 ancestral strain or Omicron than Delta were reported in unvaccinated individuals from
259 the UK and the US [15-18].
260
261 In estimation of fatality risk of COVID-19, using HFR was perhaps less biased than
262 CFR using the number of confirmed cases as the denominator because the
263 ascertainment of cases in need of hospital care would be relatively homogenous
264 particularly in places with adequate capacity in case identification and healthcare
265 services. Non-pharmaceutical and pharmaceutical measures have been widely used to
266 slow down the transmission of COVID-19 to “flatten the curve” particularly in order
267 to reduce the peak demand for hospital services. However, when healthcare services
268 are under severe pressure often due to rapidly spread of infection, both hospitalized
269 patient numbers and outcomes could be heavily affected, which would impact the
270 HFR. Extreme pressure on hospital resources during large surges in COVID
271 hospitalizations has been estimated to cause significantly increased COVID mortality
272 rates in some locations, including Italy, the United States, England, and Brazil [19-
273 23]. We estimated that the estimated HFR increased by a factor of three during the
274 peak of the Omicron BA.2 wave in Hong Kong (Table 1). Therefore, in our analysis,
275 we defined hospitalized COVID-19 patients with a set of pre-determined criteria
276 (Appendix) to allow for comparison of HFR estimates across epidemic waves.

277

278 It is well established that the severity of COVID-19 increases substantially with age
279 [24] as also shown in our age-specific estimates of HFR. The age-specific HFRs in
280 our study indicated that a much higher fatality risk in adult cases hospitalized in the
281 epidemic wave of Omicron than earlier waves, different from previous studies
282 showing reduction in disease severity [25, 26]. This likely resulted from a higher
283 proportion of older adults infected in wave 5 (Appendix) within a short time period
284 leading to less optimal clinical outcomes in patients with constrained healthcare
285 capacity [27].

286

287 By the end of wave 4 in December 2021, only around 12,000 COVID-19 cases were
288 confirmed in Hong Kong [28], with a low vaccine coverage with two or more doses of
289 either CoronaVac or BNT162b2 particularly in those ≥ 80 years of age [5]. We had a
290 unique opportunity to investigate the intrinsic HFR for the Omicron in comparison
291 with the ancestral strain by making use of fatality information collected from
292 unvaccinated individuals, and at the same time to explore the potential protection
293 against death from vaccines using vaccinated COVID-19 cases without a recorded
294 infection history. Our estimation overcame some challenges in understanding the
295 intrinsic severity of Omicron [14] while further virological and immunological
296 evidence is needed to back up the observations from epidemiologic studies. However,
297 we were only able to estimate intrinsic severity of Omicron BA.2 here because
298 COVID-19 had not circulated widely in Hong Kong prior to 2022.

299

300 The estimated lower risk of death among hospitalized COVID-19 cases was indicated
301 for vaccinees with any dose of the vaccine in comparison to the unvaccinated

302 inpatients (Table 1), largely comparable with our previous findings on the
303 effectiveness of COVID-19 vaccines against severe COVID-19 [5]. Furthermore, the
304 potential protection provided by Paxlovid or molnupiravir demonstrated in a local
305 territory-wide cohort of COVID-19 inpatients and outpatients during the Omicron
306 BA.2 wave [29, 30] perhaps could explain the lower HFR estimated in wave 6
307 compared with wave 5c (Appendix) considering a gradually expanding use of the
308 antivirals since mid-March 2022 in Hong Kong [31].

309

310 There are several limitations in our study. First, temporal comparison of severity
311 estimates over epidemic waves might be affected by varied case definitions and
312 practices in hospital admission over time [32]. We classified the severity status of
313 laboratory-confirmed COVID-19 cases based on objective measures as much as
314 possible, and defined hospitalized cases consistently throughout the study period,
315 aiming to minimize bias in the denominator of HFR, and enable valid comparisons of
316 severity measures across waves and patient groups. Second, fatality risk might differ
317 in patients admitted due to COVID-19 and those hospitalized for other reasons and
318 infected later with COVID-19, which might affect estimates of the HFR [25]. We
319 limited our analysis on HFR to hospitalized patients with the confirmation 14 days
320 earlier than the admission to exclude patients who might be infected in hospitals.
321 Third, clinical outcomes were unknown for 1.6% of the patients who were still in
322 hospital by the end of the study. The exact estimates of HFR for wave 6b might
323 change slightly if final outcomes of these patients are obtained although we do not
324 anticipate this would change our study conclusions given the small number of patients
325 involved.

326

327 In conclusion, similar intrinsic severity of Omicron to the ancestral strain and the
328 protection conferred by vaccines against fatality risk in hospitalized COVID-19
329 patients highlighted that vaccination is critically important in reducing COVID-19
330 associated health impact. Continued monitoring of epidemiologic characteristics of
331 new variants and subvariants of SARS-CoV-2 is crucial, including assessment of
332 effective severity. As testing and reporting cases in the community reduces in
333 frequency, but hospital testing likely continues in many locations, data on the HFR
334 may provide a metric that is easier to evaluate over time than CFR. Serologic data on
335 patterns in infections over time, if available, could provide a more complete picture of
336 changes over time in severity.

337

338

339 **ACKNOWLEDGMENTS**

340 The authors thank Julie Au for technical support.

341

342 **FUNDING**

343 This project was supported by a commissioned grant from the Health and Medical
344 Research Fund of the Hong Kong SAR Government (grant no. CID-HKU2-13), and
345 the Collaborative Research Scheme (project no. C7123-20G) of the Research Grants
346 Council of the Hong Kong SAR Government. BJC is supported by the RGC Senior
347 Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants
348 Council of the Hong Kong Special Administrative Region, China. The funding bodies
349 had no role in the design of the study, the collection, analysis, and interpretation of
350 data, or writing of the manuscript.

351

352 **AUTHOR CONTRIBUTIONS**

353 The study was conceived by BJC and PW. JYW, PW and JKC analyzed the data.
354 JYW wrote the first draft of the manuscript. All authors provided critical review and
355 revision of the text and approved the final version.

356

357 **DATA SHARING STATEMENT**

358 Restrictions apply to the availability of these data. The hospitalization and mortality
359 data are available for access with the permission from the Hospital Authority and the
360 Census and Statistics Department of Hong Kong.

361

362 **DECLARATION OF INTERESTS**

363 BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna,
364 Pfizer, Roche and Sanofi Pasteur. The other authors report no other potential conflicts
365 of interest.

366 **REFERENCES**

- 367 1. Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non-
368 pharmaceutical interventions against coronavirus disease 2019 and influenza
369 in Hong Kong: an observational study. *Lancet Public Health* **2020**;5(5):e279-
370 e88.
- 371 2. To KK, Cheng VC, Cai JP, et al. Seroprevalence of SARS-CoV-2 in Hong
372 Kong and in residents evacuated from Hubei province, China: a multicohort
373 study. *Lancet Microbe* **2020**;1(3):e111-e8.
- 374 3. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-
375 CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022. *Emerg*
376 *Infect Dis* **2022**;28(9):1856-8.
- 377 4. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-
378 CoV-2 Omicron variant in southern Africa. *Nature* **2022**;603(7902):679-86.
- 379 5. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two,
380 and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong
381 Kong: a population-based observational study. *Lancet Infect Dis*
382 **2022**;22(10):1435-43.
- 383 6. Xiao J, Cheung JK, Wu P, et al. Temporal changes in factors associated with
384 COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial
385 cross-sectional surveys. *Lancet Reg Health West Pac* **2022**;23:100441.
- 386 7. Wong JY, Wu P, Nishiura H, et al. Infection fatality risk of the pandemic
387 A(H1N1)2009 virus in Hong Kong. *Am J Epidemiol* **2013**;177(8):834-40.
- 388 8. Wong JY, Kelly H, Cheung CM, et al. Hospitalization Fatality Risk of
389 Influenza A(H1N1)pdm09: A Systematic Review and Meta-Analysis. *Am J*
390 *Epidemiol* **2015**;182(4):294-301.

- 391 9. The Government of the Hong Kong Special Administrative Region. Selecting
392 and using rapid antigen tests.
393 (<https://www.info.gov.hk/gia/general/202202/27/P2022022600796.htm>).
394 (Accessed 6 February 2023).
- 395 10. The Government of the Hong Kong Special Administrative Region. CHP
396 investigates 82 confirmed and 132 asymptomatic additional SARS-CoV-2
397 virus cases with 17 cases pending status by nucleic acid tests as well as
398 verified 258 cases tested positive by rapid antigen tests.
399 (<https://www.info.gov.hk/gia/general/202206/07/P2022060700716.htm>).
400 (Accessed 30 December 2022).
- 401 11. Wong JY, Wu P, Lau EH, et al. Real-time estimation of the hospitalization
402 fatality risk of influenza A(H1N1)pdm09 in Hong Kong. *Epidemiol Infect*
403 **2016**;144(8):1579-83.
- 404 12. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity
405 of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.
406 *Lancet* **2022**;399(10323):437-46.
- 407 13. Hui KPY, Ng KC, Ho JCW, et al. Replication of SARS-CoV-2 Omicron BA.2
408 variant in ex vivo cultures of the human upper and lower respiratory tract.
409 *EBioMedicine* **2022**;83:104232.
- 410 14. Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of
411 the SARS-CoV-2 Omicron Variant. *N Engl J Med* **2022**;386(7):e14.
- 412 15. Bast E, Tang F, Dahn J, et al. Increased risk of hospitalisation and death with
413 the delta variant in the USA. *Lancet Infect Dis* **2021**;21(12):1629-30.
- 414 16. Robinson ML, Morris CP, Betz JF, et al. Impact of SARS-CoV-2 variants on
415 inpatient clinical outcome. *Clin Infect Dis* **2022** (Online ahead of print).

- 416 17. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of
417 hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529)
418 and delta (B.1.617.2) variants in England: a cohort study. *Lancet*
419 **2022**;399(10332):1303-12.
- 420 18. Greene SK, Levin-Rector A, Kyaw NTT, et al. Comparative hospitalization
421 risk for SARS-CoV-2 Omicron and Delta variant infections, by variant
422 predominance periods and patient-level sequencing results, New York City,
423 August 2021-January 2022. *Influenza Other Respir Viruses*
424 **2023**;17(1):e13062.
- 425 19. Volpato S, Landi F, Incalzi RA. A Frail Health Care System for an Old
426 Population: Lesson form the COVID-19 Outbreak in Italy. *J Gerontol A Biol*
427 *Sci Med Sci* **2020**;75(9):e126-e7.
- 428 20. Dang A, Thakker R, Li S, et al. Hospitalizations and Mortality From Non-
429 SARS-CoV-2 Causes Among Medicare Beneficiaries at US Hospitals During
430 the SARS-CoV-2 Pandemic. *JAMA Netw Open* **2022**;5(3):e221754.
- 431 21. Gray WK, Navaratnam AV, Day J, et al. COVID-19 hospital activity and in-
432 hospital mortality during the first and second waves of the pandemic in
433 England: an observational study. *Thorax* **2022**;77(11):1113-20.
- 434 22. Brizzi A, Whittaker C, Servo LMS, et al. Author Correction: Spatial and
435 temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. *Nat*
436 *Med* **2022**;28(7):1509.
- 437 23. Janke AT, Mei H, Rothenberg C, et al. Analysis of Hospital Resource
438 Availability and COVID-19 Mortality Across the United States. *J Hosp Med*
439 **2021**;16(4):211-4.

- 440 24. Levin AT, Hanage WP, Owusu-Boaitey N, et al. Assessing the age specificity
441 of infection fatality rates for COVID-19: systematic review, meta-analysis,
442 and public policy implications. *Eur J Epidemiol* **2020**;35(12):1123-38.
- 443 25. Reichert E, Schaeffer B, Gantt S, et al. Methods for early characterisation of
444 the severity and dynamics of SARS-CoV-2 variants: a population-based time
445 series analysis in South Africa. *Lancet Microbe* **2022**;3(10):e753-e61.
- 446 26. Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19
447 in patients admitted to hospital during the omicron wave in South Africa: a
448 retrospective observational study. *Lancet Glob Health* **2022**;10(7):e961-e9.
- 449 27. Ko YK, Murayama H, Yamasaki L, et al. Age-Dependent Effects of COVID-
450 19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan.
451 *Emerg Infect Dis* **2022**;28(9):1777-84.
- 452 28. The Government of the Hong Kong Special Administrative Region. CHP
453 investigates 12 additional confirmed cases of COVID-19 and 11 additional
454 Omicron cases.
455 (<https://www.info.gov.hk/gia/general/202112/30/P2021123000612.htm>).
456 (Accessed 20 January 2023).
- 457 29. Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of
458 molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation,
459 and in-hospital outcomes among community-dwelling, ambulatory patients
460 with confirmed SARS-CoV-2 infection during the omicron wave in Hong
461 Kong: an observational study. *Lancet* **2022**;400(10359):1213-22.
- 462 30. Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of early
463 molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19
464 without supplemental oxygen requirement on admission during Hong Kong's

- 465 omicron BA.2 wave: a retrospective cohort study. *Lancet Infect Dis*
466 **2022**;22(12):1681-93.
- 467 31. The Government of the Hong Kong Special Administrative Region. First
468 shipment of COVID-19 oral drug Paxlovid distributed to HA for application
469 (with photos).
470 (<https://www.info.gov.hk/gia/general/202203/15/P2022031500280.htm>).
471 (Accessed 20 January 2023).
- 472 32. Tsang TK, Wu P, Lin Y, et al. Effect of changing case definitions for COVID-
473 19 on the epidemic curve and transmission parameters in mainland China: a
474 modelling study. *Lancet Public Health* **2020**;5(5):e289-e96.
475

Table 1. Logistic regression of risk factors of mortality among hospitalized local COVID-19 cases confirmed in wave 5 predominated by Omicron subvariants from 31 December 2021 to 22 May 2022.

	Sample size (n)	Deaths (%) ^a	Non-discharged cases (%) ^a	Odds ratio (95% CI) ^b
Age, years				
<18	508	5/508 (1.0)	0/508 (0.0)	0.03 (0.01, 0.07)
18-44	683	61/683 (8.9)	23/683 (3.4)	0.45 (0.33, 0.59)
45-64	2,574	573/2,574 (22.3)	68/2,574 (2.6)	1.00
65-79	6,091	1,899/6,091 (31.2)	28/6,091 (0.5)	1.50 (1.34, 1.68)
≥ 80	12,748	5,850/12,748 (45.9)	21/12,748 (0.2)	2.88 (2.59, 3.21)
Gender				
Male	12,845	5,016/12,845 (39.1)	85/12,845 (0.7)	1.00
Female	9,759	3,372/9,759 (34.6)	55/9,759 (0.6)	0.76 (0.72, 0.81)
RCHE resident				
No	12,622	3,997/12,622 (31.7)	125/12,622 (1.0)	1.00
Yes	9,982	4,391/9,982 (44.0)	15/9,982 (0.2)	1.17 (1.10, 1.24)
Comorbidities^c				
Diabetes	5,119	1,959/5,119 (38.3)	20/5,119 (0.4)	0.96 (0.90, 1.03)
Malignant neoplasms	2,135	997/2,135 (46.7)	8/2,135 (0.4)	2.03 (1.84, 2.24)
Cardiovascular diseases	9,987	4,420/9,987 (44.3)	47/9,987 (0.5)	1.47 (1.39, 1.56)
Vaccination combinations				
Unvaccinated	14,180	6,047/14,180 (42.6)	102/14,180 (0.7)	1.00
One dose BNT162b2	453	127/453 (28.0)	2/453 (0.4)	0.67 (0.54, 0.84)
One dose CoronaVac	3,681	1,200/3,681 (32.6)	10/3,681 (0.3)	0.71 (0.65, 0.77)
Two doses BNT162b2	955	194/955 (20.3)	7/955 (0.7)	0.53 (0.44, 0.63)
Two doses CoronaVac	2,794	738/2,794 (26.4)	18/2,794 (0.6)	0.58 (0.53, 0.64)
Three doses BNT162b2	171	20/171 (11.7)	0/171 (0.0)	0.31 (0.18, 0.49)
Three doses CoronaVac	311	47/311 (15.1)	1/311 (0.3)	0.36 (0.26, 0.49)
Two doses CoronaVac with BNT162b2 booster	59	15/59 (25.4)	0/59 (0.0)	0.71 (0.37, 1.29)

Antiviral use

None	18,972	7,448/18,972 (39.3)	113/18,972 (0.6)	1.00
Paxlovid	734	117/734 (15.9)	4/734 (0.5)	0.39 (0.32, 0.48)
Molnupiravir	2,898	823/2,898 (28.4)	23/2,898 (0.8)	0.62 (0.56, 0.68)

Time of confirmation

Wave 5a: 31/12 - 13/2 ^d	282	47/282 (16.7)	0/282 (0.0)	1.00
Wave 5b (by week):				
14/2 - 20/2	1,081	356/1,081 (32.9)	7/1,081 (0.6)	1.92 (1.36, 2.77)
21/2 – 27/2 (Peak)	2,509	1,128/2,509 (45.0)	15/2,509 (0.6)	3.05 (2.19, 4.32)
28/2 - 6/3	4,550	2,018/4,550 (44.4)	38/4,550 (0.8)	2.96 (2.14, 4.18)
7/3 - 13/3	4,783	1,913/4,783 (40.0)	50/4,783 (1.0)	2.49 (1.79, 3.51)
14/3 - 20/3	4,479	1,565/4,479 (34.9)	19/4,479 (0.4)	2.10 (1.52, 2.97)
21/3 - 27/3	2,222	671/2,222 (30.2)	3/2,222 (0.1)	1.93 (1.38, 2.74)
28/3 – 3/4	1,229	332/1,229 (27.0)	3/1,229 (0.2)	1.75 (1.24, 2.53)
4/4 - 10/4	590	156/590 (26.4)	3/590 (0.5)	1.80 (1.23, 2.66)
11/4 - 17/4	351	81/351 (23.1)	0/351 (0.0)	1.52 (1.00, 2.32)
18/4 - 24/4	191	46/191 (24.1)	0/191 (0.0)	1.74 (1.07, 2.82)
25/4 - 29/4	114	28/114 (24.6)	1/114 (0.9)	1.63 (0.93, 2.83)
Wave 5c: 30/4 – 22/5 ^d	223	47/223 (21.1)	1/223 (0.4)	1.47 (0.91, 2.35)

^a Proportions presented in the columns were defined as the number of events over the number of cases in each strata that were included in the analysis

^b Analysis was based on COVID-19 cases confirmed between 31/12/2021 and 22/5/2022, classified with severity of severe or above based on criteria outlined in the Appendix and with confirmation-to-admission delays of no more than 14 days (N=22,604)

^c Odds ratios were determined by comparing patients that have the listed comorbidities with patients that do not

^d Wave 5a (31/12/2021 - 13/2/2022); Wave 5b (14/2/2022 - 29/4/2022); Wave 5c (30/4/2022 – 22/5/2022)

Table 2. Logistic regression of risk factors of mortality among hospitalized local COVID-19 cases that did not receive any dose of COVID-19 vaccine, waves 1-4 vs wave 5a.

	Sample size (n)	Deaths (%) ^a	Non-discharged cases (%) ^a	Odds ratio (95% CI) ^b
Age, years				
<18	45	0/45 (0.0)	0/45 (0.0)	0.00 (0.00, 0.00)
18-44	256	2/256 (0.8)	0/256 (0.0)	0.41 (0.06, 1.43)
45-64	806	19/806 (2.4)	1/806 (0.1)	1.00
65-79	708	85/708 (12.0)	0/708 (0.0)	4.80 (2.94, 8.26)
≥ 80	345	135/345 (39.1)	1/345 (0.3)	20.81 (12.66, 35.95)
Gender				
Male	1,222	146/1,222 (11.9)	2/1,222 (0.2)	1.00
Female	938	95/938 (10.1)	0/938 (0.0)	0.68 (0.49, 0.92)
RCHE resident				
No	2,107	220/2,107 (10.4)	2/2,107 (0.1)	1.00
Yes	53	21/53 (39.6)	0/53 (0.0)	1.39 (0.63, 3.06)
Comorbidities				
None	1,493	85/1,493 (5.7)	2/1,493 (0.1)	1.00
At least one comorbidity ^c	667	156/667 (23.4)	0/667 (0.0)	2.89 (2.13, 3.95)
Confirmation period^d				
Waves 1-4	1,974	198/1,974 (10.0)	2/1,974 (0.1)	1.00
Wave 5a	186	43/186 (23.1)	0/186 (0.0)	1.08 (0.61, 1.83)

^a Proportions presented in the columns were defined as the number of events over the number of cases in each strata that were included in the analysis

^b Analysis was based on COVID-19 cases with dates of confirmation during Waves 1-4 or Wave 5a, classified with severity of severe or above based on criteria outlined in the Appendix and with confirmation-to-admission delays of no more than 14 days (N=2,160)

^c If patients have at least one of the following comorbidities: diabetes, malignant neoplasms and cardiovascular diseases

^d Waves 1-4 (23/1/2020 – 30/12/2021); Wave 5a (31/12/2021 – 13/2/2022)




Figure 1: Local COVID-19 cases and deaths, estimated case hospitalization risk and estimated hospitalization fatality risk in Hong Kong, 2020-2022. (A) Epidemic curve of daily local COVID-19 cases and deaths in wave 1 to wave 6. Cases were stratified by date of confirmation and deaths were stratified by date of death. (B) Weekly effective case hospitalization risk. (C) Weekly effective hospitalization fatality risk. Estimates in panels (B) and (C) were only plotted for weeks when ≥ 35 local cases and ≥ 15 hospitalized cases were confirmed for at least 4 consecutive weeks.




Figure 2: Age-specific estimates of the case hospitalization and hospitalization fatality risks for COVID-19 in waves 1-4, wave 5 and wave 6 in Hong Kong, compared with estimates of the hospitalization fatality risk for all hospitalized patients with pandemic influenza A(H1N1)pdm09 in 2009. (A) Case hospitalization risk in waves 1-4, 5 and 6 by age group, compared with pandemic influenza (H1N1)pdm09 in 2009. (B) Hospitalization fatality risk in waves 1-4, 5 and 6 by age group, compared with pandemic influenza (H1N1)pdm09 in 2009.




Figure 3: Age-specific estimates of the hospitalization fatality risk for COVID-19 among unvaccinated patients in Hong Kong by waves and relative risks of hospitalization fatality risk in wave 5a compared to waves 1-4. (A) Fatality risk among unvaccinated hospitalized local COVID-19 cases, in waves 1-4 compared with wave 5a by age group. (B) Relative risk of hospitalization fatality risk in wave 5a compared to waves 1-4 by age group.